177 related articles for article (PubMed ID: 20836132)
1. Whether to target single or multiple CDKs for therapy? That is the question.
Węsierska-Gądek J; Maurer M; Zulehner N; Komina O
J Cell Physiol; 2011 Feb; 226(2):341-9. PubMed ID: 20836132
[TBL] [Abstract][Full Text] [Related]
2. Novel potent pharmacological cyclin-dependent kinase inhibitors.
Węsierska-Gądek J; Chamrád I; Kryštof V
Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
[TBL] [Abstract][Full Text] [Related]
3. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
4. [Cyclin-dependent kinase inhibitors in mammal cells].
Jiang H; Wang YC
Sheng Li Ke Xue Jin Zhan; 1996 Apr; 27(2):107-12. PubMed ID: 9592231
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1.
Korkolopoulou P; Christodoulou P; Konstantinidou AE; Thomas-Tsagli E; Kapralos P; Davaris P
Hum Pathol; 2000 Jun; 31(6):751-60. PubMed ID: 10872671
[TBL] [Abstract][Full Text] [Related]
6. Multiple functions of p27(Kip1) and its alterations in tumor cells: a review.
Sgambato A; Cittadini A; Faraglia B; Weinstein IB
J Cell Physiol; 2000 Apr; 183(1):18-27. PubMed ID: 10699962
[TBL] [Abstract][Full Text] [Related]
7. Cyclins and related kinases in cancer cells.
Malumbres M
J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
[TBL] [Abstract][Full Text] [Related]
8. p27: a pleiotropic regulator of cellular phenotype and a target for cell cycle dysregulation in cancer.
Desdouets C; Bréchot C
Pathol Biol (Paris); 2000 Apr; 48(3):203-10. PubMed ID: 10858954
[TBL] [Abstract][Full Text] [Related]
9. Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin.
Rodriguez-Puebla ML; LaCava M; Gimenez-Conti IB; Johnson DG; Conti CJ
Oncogene; 1998 Oct; 17(17):2251-8. PubMed ID: 9811455
[TBL] [Abstract][Full Text] [Related]
10. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
Węsierska-Gądek J; Kramer MP
Expert Opin Investig Drugs; 2011 Dec; 20(12):1611-28. PubMed ID: 22017180
[TBL] [Abstract][Full Text] [Related]
11. Regulation of expression and activity of distinct pRB, E2F, D-type cyclin, and CKI family members during terminal differentiation of P19 cells.
Gill RM; Slack R; Kiess M; Hamel PA
Exp Cell Res; 1998 Oct; 244(1):157-70. PubMed ID: 9770359
[TBL] [Abstract][Full Text] [Related]
12. Cell cycle control in breast cancer cells.
Caldon CE; Daly RJ; Sutherland RL; Musgrove EA
J Cell Biochem; 2006 Feb; 97(2):261-74. PubMed ID: 16267837
[TBL] [Abstract][Full Text] [Related]
13. P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
Grimison B; Langan TA; Sclafani RA
Cell Growth Differ; 2000 Oct; 11(10):507-15. PubMed ID: 11063124
[TBL] [Abstract][Full Text] [Related]
14. Anti-sense oligonucleotide of p21(waf1/cip1) prevents interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells.
Liu J; Estes ML; Drazba JA; Liu H; Prayson R; Kondo S; Jacobs BS; Barnett GH; Barna BP
Oncogene; 2000 Feb; 19(5):661-9. PubMed ID: 10698511
[TBL] [Abstract][Full Text] [Related]
15. Expression of positive and negative regulators of cell cycle during wound healing.
Zhu X; Di Y; Hu C; Wang Z
Chin Med J (Engl); 2002 Mar; 115(3):326-30. PubMed ID: 11940356
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Blachly JS; Byrd JC; Grever M
Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
[TBL] [Abstract][Full Text] [Related]
18. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase modulators and cancer therapy.
Gallorini M; Cataldi A; di Giacomo V
BioDrugs; 2012 Dec; 26(6):377-91. PubMed ID: 22928661
[TBL] [Abstract][Full Text] [Related]
20. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors.
Cirillo D; Pentimalli F; Giordano A
Curr Med Chem; 2011; 18(19):2854-66. PubMed ID: 21651493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
